Umeklidinium bromida

Umeklidinium bromida
Nama sistematis (IUPAC)
	Difenil-[1-(2-fenilmetoksietil)-1-azoniabisiklo[2.2.2]oktan-4-il]metanol bromida
Data klinis
Nama dagang	Incruse Ellipta
Data lisensi	US Daily Med:bromide pranala
Kat. kehamilan	?
Status hukum	Harus dengan resep dokter (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US) ℞ Preskripsi saja
Rute	Inhalasi (Inhaler serbuk kering)
Data farmakokinetik
Ikatan protein	~89%
Metabolisme	Hati (CYP2D6)
Waktu paruh	11 jam
Ekskresi	Feses (58%) dan urin (22%)
Pengenal
Nomor CAS	869113-09-7
Kode ATC	R03BB07 ; R03AL03 (+vilanterol)
PubChem	CID 11519069
ChemSpider	9693857
UNII	7AN603V4JV
KEGG	D10181
ChEBI	CHEBI:79040
Sinonim	GSK573719A
Data kimia
Rumus	C29H34BrNO2
SMILES	eMolecules & PubChem
	InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1; Key:PEJHHXHHNGORMP-UHFFFAOYSA-M;

Umeklidinium bromida adalah antagonis muskarinik kerja panjang yang disetujui untuk pengobatan pemeliharaan penyakit paru obstruktif kronik (PPOK).^[1] Obat ini juga disetujui untuk indikasi ini dalam kombinasi dengan vilanterol (sebagai umeklidinium bromida/vilanterol)^[2]^[3] dan juga sebagai kombinasi tiga terapi sebagai flutikason furoat/umeklidinium bromida/vilanterol.^[4] Obat ini tercantum dalam Daftar Obat Esensial Organisasi Kesehatan Dunia.^[5]

Referensi

^ ^a ^b "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Diarsipkan dari versi asli (PDF) tanggal 10 July 2018. Diakses tanggal 22 February 2016.
^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
^ "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Diakses tanggal 11 July 2020.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533  . WHO/MHP/HPS/EML/2021.02.

[PI-1] "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Diarsipkan dari versi asli (PDF) tanggal 10 July 2018. Diakses tanggal 22 February 2016.

[2] Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.

[3] "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.

[Trelegy_Ellipta_PI-4] "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Diakses tanggal 11 July 2020.

[WHO22nd-5] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533  . WHO/MHP/HPS/EML/2021.02.

[1]

[2]

[3]

[4]

[5]